InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
June 21, 2023 07:00 ET
|
InflaRx N.V.
Gohibic is now commercially available for hospitals in the U.S.Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for treatment of certain critically ill COVID-19...
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
April 04, 2023 14:55 ET
|
InflaRx N.V.
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III...
Veru Inc. Sued By Block & Leviton LLP for Securities Law Violations
January 10, 2023 11:00 ET
|
Block & Leviton LLP
BOSTON, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of...
ROSEN, A LEADING LAW FIRM, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU
December 24, 2022 15:58 ET
|
The Rosen Law Firm PA
WHY: NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and...
ROSEN, A LEADING LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – EIGR
November 11, 2022 10:26 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Eiger...
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022 10:30 ET
|
BioNTech SE
NEW YORK and MAINZ, GERMANY, OCTOBER 12, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use...
Pfizer und BioNTech reichen Antrag auf Notfallzulassung für Auffrischungsimpfung mit einem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Kinder von 5 bis 11 Jahren bei der FDA ein
September 26, 2022 06:45 ET
|
BioNTech SE
NEW YORK und MAINZ, Deutschland, 26. September 2022 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass sie bei der US-amerikanischen...
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
September 26, 2022 06:45 ET
|
BioNTech SE
NEW YORK and MAINZ, GERMANY, September 26, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Humanigen, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – HGEN
September 17, 2022 11:00 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 17, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and...
Pfizer und BioNTech erhalten FDA-Notfallzulassung für Auffrischungsimpfung mit an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff für Personen ab 12 Jahren
August 31, 2022 10:12 ET
|
BioNTech SE
Die Notfallzulassung basiert auf klinischen und präklinischen Daten sowie Daten zur Herstellung von an Omikron angepassten bivalenten ImpfstoffenDer bivalente Omikron BA.4/BA.5 Impfstoff von Pfizer...